Gen1E-1124 is under clinical development by GEn1E Lifesciences and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData, Phase I drugs for Kidney Disease (Nephropathy) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gen1E-1124’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gen1E-1124 overview

Gen1E-1124 is under development for the treatment of acute lung injury (ALI), acute respiratory distress syndrome (ARDS), COVID-19 pneumonia and unspecified renal disease (nephrology). The drug candidates act by targeting mitogen activated protein kinase 14 (MAP Kinase p38 Alpha). It is administered through intravenous route.

GEn1E Lifesciences overview

GEn1E Lifesciences is biotechnology company which is engaged in the research and development of immunomodulatory therapies for rare & inflammatory diseases. It is headquartered in Palo Alto, California, the US.

For a complete picture of Gen1E-1124’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.